Mongolian pharmaceutical manufacturer Monos to expand technological capacity
The EBRD is lending US$ 8 million to Monos Holding LLC to help the firm invest in new equipment to expand manufacturing capacity, develop training, and reorganize long-term capital financing.
Being in operation for some three decades, Monos is one of the first private companies in Mongolia that has various operations including pharmaceutical manufacturing and study of drug research through prioritizing production of effective and high quality medicines. The EBRD is lending US$ 8 million to Monos Holding LLC – a holding company of Monos Group, a leading pharmaceutical conglomerate in Mongolia – to help the firm invest in new equipment to expand manufacturing capacity, develop training, and reorganize long-term capital financing to support its wholesale business. The five-year loan will enable Monos Group to become more competitive, by supporting the certification of manufacturing capacity and improving employee skills through training. By the end of 2019 the firm aims to secure Good Manufacturing Practice (GMP) certification and to have at least 30 new employees who are trained regularly according to GMP standards.
Views: 1078
Tweet